The Role and Therapeutic Implication of HDAC8 in Neuroblastoma

Neuroblastoma lineage arises from a neural crest origin and is a typically common tumor among the pediatric population. Survival rate for this disease has improved over the years, however, patients with MYCN amplification correlate with a poor prognosis, warranting improved therapies. The utility and efficacy of pan-HDAC inhibitors for the treatment for various solid tumors has increased with promising results. Isoform-specific HDAC inhibitors have been developed to improve the therapeutic window and reduce side effects. The role of isoform-specific HDAC inhibitors, namely HDAC8 inhibitors, has recently been investigated in numerous tumor histologies, including neuroblastoma, among other neural crest-derived tumors. Long term pan-HDAC inhibition has been demonstrated to induce differentiation and regression to a benign-like phenotype in neuroblastoma in vivo. HDAC8 inhibition has been shown to inhibit growth and induce differentiation in neuroblastoma cells. The role of HDAC8 inhibition on neuroblastoma and regression of the disease merits further investigation.


Gonzalo Lopez and Raphael Pollock

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+

Recommended Conferences

  • 10th International Conference on Vascular Dementia
    February 22-23, 2018 Paris, France
  • 21st World Congress on Neurology and Therapeutics
    March 15-17, 2018 London, UK
  • 11th International Conference on Alzheimers Disease & Dementia 
    March 29-30, 2018 ,Vienna , Austria
  • 7th International Conference on Brain and Neurological Disorders 
    Apr 10-12, 2018 Amsterdam, Netherlands
Flyer image

Abstracted/Indexed in

  • Google Scholar
  • Directory of Research Journal Indexing (DRJI)
  • WorldCat